Trump plans steep tariffs on generic drugs starting in 2028 to spur U.S. production

• The escalating tariff structure serves as 'a penalty' for companies that fail to build U.S. manufacturing facilities within the two-year grace period, while patented and branded drugs face no changes
• India's pharmaceutical sector faces significant impact as Indian companies supply billions in pharma exports annually to the U.S., mostly generic drugs, while Chinese firms dominate active ingredient production
• Over a dozen major drugmakers including major pharmaceutical companies have signed pricing agreements with Trump that exempt them from tariffs for three years in exchange for lowering drug prices

SUMMARY

President Trump announced a phased tariff plan on imported generic drugs designed to incentivize domestic pharmaceutical production. Beginning August 1, generic drug imports will face zero tariffs for a two-year grace period. A 100% tariff will then take effect in August 2028, escalating to 200% one year later in 2029.

Key Details:

• The tariff schedule applies only to generic drugs; patented and branded medications remain exempt
• The policy aims to penalize companies that fail to establish U.S.-based manufacturing plants and facilities within the two-year window
• Trump previously imposed 100% tariffs on certain pharmaceutical products and ingredients on April 2, while exempting generics and biosimilars at that time
• Large drugmakers received 360 days before facing 100% tariffs; smaller firms relying on contract manufacturers received 180 days

Companies and Agreements:

Over a dozen major pharmaceutical companies have signed pricing agreements with the Trump administration to reduce costs on new and existing medicines. These deals tie U.S. drug prices to lower international benchmarks under Trump's "most-favored-nation" pricing policy and provide three-year tariff exemptions.

Market Implications:

The stakes are particularly high for India, whose pharmaceutical companies export billions of dollars in generic drugs to the U.S. annually. Chinese firms dominate production of active pharmaceutical ingredients including amoxicillin and heparin, making them vulnerable to the tariff escalation.

The policy represents Trump's broader strategy of using tariff threats and pricing policies to pressure drugmakers into offering Americans prices comparable to other high-income countries while simultaneously reshoring pharmaceutical manufacturing.